{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:05:39Z","timestamp":1793246739037,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001962","name":"World Anti-Doping Agency","doi-asserted-by":"crossref","award":["T20M03RV"],"award-info":[{"award-number":["T20M03RV"]}],"id":[{"id":"10.13039\/501100001962","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fundaci\u00f3 Instituci\u00f3 dels Centres de Recerca de Catalunya"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40262-026-01665-x","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T17:24:34Z","timestamp":1782321874000},"page":"1243-1256","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Revisited Pharmacokinetic Profiles of Methylprednisolone in Plasma and Urine After Single and Multiple Oral Administrations: Relevance in Sports Drug Testing"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0729-4470","authenticated-orcid":false,"given":"Sergi","family":"Coll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4153-6656","authenticated-orcid":false,"given":"Claudia","family":"Bressan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9504-4767","authenticated-orcid":false,"given":"N\u00faria","family":"Monfort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3791-8814","authenticated-orcid":false,"given":"Ana","family":"Aldea-Perona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7321-6732","authenticated-orcid":false,"given":"Marcel\u00b7l\u00ed","family":"Carb\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1413-8890","authenticated-orcid":false,"given":"Rosa","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"issue":"1","key":"1665_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/edrv-5-1-1","volume":"5","author":"ME Keller-Wood","year":"1984","unstructured":"Keller-Wood ME, Dallman MF. Corticosteroid inhibition of ACTH secretion. Endocr Rev. 1984;5(1):1\u201324. https:\/\/doi.org\/10.1210\/edrv-5-1-1.","journal-title":"Endocr Rev"},{"issue":"9203","key":"1665_CR2","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/S0140-6736(99)06290-X","volume":"355","author":"C Henzen","year":"2000","unstructured":"Henzen C, Suter A, Lerch E, Urbinelli R, Schormo XH. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet. 2000;355(9203):542\u20135. https:\/\/doi.org\/10.1016\/S0140-6736(99)06290-X.","journal-title":"Lancet"},{"issue":"9","key":"1665_CR3","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1249\/mss.0b013e3180dc992c","volume":"39","author":"A Arletazz","year":"2007","unstructured":"Arletazz A, Portier H, Lecoq AM, Rieth N, De Ceaurriz J, Collomp K. Effects of short-term prednisolone intake during submaximal exercise. Med Sci Sports Exerc. 2007;39(9):1672\u20138. https:\/\/doi.org\/10.1249\/mss.0b013e3180dc992c.","journal-title":"Med Sci Sports Exerc"},{"issue":"12","key":"1665_CR4","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1136\/bjsm.2007.043083","volume":"42","author":"K Collomp","year":"2008","unstructured":"Collomp K, Arlettaz A, Portier H, Lecoq AM, Le Panse B, Rieth N, et al. Short-term glucocorticoid intake combined with intense training on performance and hormonal responses. Br J Sports Med. 2008;42(12):983\u20138. https:\/\/doi.org\/10.1136\/bjsm.2007.043083.","journal-title":"Br J Sports Med"},{"issue":"5","key":"1665_CR5","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1113\/jphysiol.2007.143073","volume":"586","author":"NB Nordsborg","year":"2008","unstructured":"Nordsborg NB, Ovesen J, Thomassen M, Zangenberg M, Jona C, Iaia FM, et al. Effect of methylprednisolone on skeletal muscle Na+, K+ pump subunit specific expression and K+ homeostasis during exercise in humans. J Physiol. 2008;586(5):1447\u201359. https:\/\/doi.org\/10.1113\/jphysiol.2007.143073.","journal-title":"J Physiol"},{"issue":"4","key":"1665_CR6","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00421-009-1149-8","volume":"107","author":"B Le Panse","year":"2009","unstructured":"Le Panse B, Thomasson R, Jollin L, Lecoq AM, Le Panse B, Rieth N, et al. Short-term glucocorticoid intake improves exercise endurance in healthy recreationally trained women. Eur J Appl Physiol. 2009;107(4):437\u201343. https:\/\/doi.org\/10.1007\/s00421-009-1149-8.","journal-title":"Eur J Appl Physiol"},{"issue":"3","key":"1665_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3810\/psm.2010.10.1817","volume":"38","author":"M Duclos","year":"2010","unstructured":"Duclos M. Evidence on ergogenic action of glucocorticoids as a doping agent risk. Physician Sportsmed. 2010;38(3):121\u20137. https:\/\/doi.org\/10.3810\/psm.2010.10.1817.","journal-title":"Physician Sportsmed."},{"issue":"2","key":"1665_CR8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00421-013-2784-7","volume":"114","author":"RA Casuso","year":"2014","unstructured":"Casuso RA, Melskens L, Bruhn T, Secher NH, Nordsborg NB. Glucocorticoids improve high-intensity exercise performance in humans. Eur J Appl Physiol. 2014;114(2):419\u201324. https:\/\/doi.org\/10.1007\/s00421-013-2784-7.","journal-title":"Eur J Appl Physiol"},{"key":"1665_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/jsteroids.2016.09.008","volume":"115","author":"K Collomp","year":"2016","unstructured":"Collomp K, Arlettaz A, Buisson C, Lecoq AM, Mongongu C. Glucocorticoid administration in athletes: performance, metabolism and detection. Steroids. 2016;115:193\u2013202. https:\/\/doi.org\/10.1016\/jsteroids.2016.09.008.","journal-title":"Steroids"},{"key":"1665_CR10","doi-asserted-by":"crossref","unstructured":"Ventura R, Daley-Yates P, Mazzoni I, Collomp K, Saugy M, Buttgereit F, et al. A novel approach to improve detection of glucocorticoid doping in sport with new guidance for physicians prescribing for athletes. Br J Sport Med. 2021 Apr 20:bjsports-2020-103512. [Epub ahead of print].","DOI":"10.1136\/bjsports-2020-103512"},{"issue":"1","key":"1665_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00216-011-4744-6","volume":"400","author":"A Panusa","year":"2011","unstructured":"Panusa A, Regazzoni L, Aldini G, Orioli M, Giombini A, Minghetti P, et al. Urinary profile of methylprednisolone acetate metabolites in patients following intra-articular and intramuscular administration. Anal Bioanal Chem. 2011;400(1):255\u201367. https:\/\/doi.org\/10.1007\/s00216-011-4744-6.","journal-title":"Anal Bioanal Chem"},{"key":"1665_CR12","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jsbmb.2013.05.019","volume":"138","author":"X Matabosch","year":"2013","unstructured":"Matabosch X, Pozo OJ, Monfort N, P\u00e9rez-Ma\u00f1\u00e1 C, Farr\u00e9 M, Marcos J, et al. Urinary profile of methylprednisolone metabolites after oral and topical administrations. J Steroid Biochem Mol Biol. 2013;138:214\u201321. https:\/\/doi.org\/10.1016\/j.jsbmb.2013.05.019.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"1","key":"1665_CR13","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/FTD.0b013e3182787b20","volume":"35","author":"X Matabosch","year":"2013","unstructured":"Matabosch X, Pozo OJ, P\u00e9rez-Ma\u00f1\u00e1 C, Farr\u00e9 M, Marcos J, Segura J, et al. Discrimination of prohibited oral use from authorized inhaled treatment of budesonide in sports. Ther Drug Monit. 2013;35(1):118\u201328. https:\/\/doi.org\/10.1097\/FTD.0b013e3182787b20.","journal-title":"Ther Drug Monit"},{"key":"1665_CR14","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jsbmb.2014.09.018","volume":"145","author":"X Matabosch","year":"2014","unstructured":"Matabosch X, Pozo OJ, P\u00e9rez-Ma\u00f1\u00e1 C, Papaseit E, Marcos J, Segura J, et al. Evaluation of the reporting level to detect triamcinolone acetonide misuse in sports. J Steroid Biochem Mol Biol. 2014;145:94\u2013102. https:\/\/doi.org\/10.1016\/j.jsbmb.2014.09.018.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1665_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.forsciint.2014.07.024","volume":"244","author":"CW Chang","year":"2014","unstructured":"Chang CW, Huang TY, Tseng YC, Chang-Chien GP, Lin SF, Hsu MC. Positive doping results caused by the single-dose local injection of triamcinolone acetonide. Forensic Sci Int. 2014;244:1\u20136. https:\/\/doi.org\/10.1016\/j.forsciint.2014.07.024.","journal-title":"Forensic Sci Int"},{"issue":"8","key":"1665_CR16","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/dta.1770","volume":"7","author":"X Matabosch","year":"2015","unstructured":"Matabosch X, Pozo OJ, Monfort N, Perez-Ma\u00f1a C, Farr\u00e9 M, Segura J, et al. Detection and characterization of betamethasone metabolites in human urine by LC-MS\/MS. Drug Test Anal. 2015;7(8):663\u201372. https:\/\/doi.org\/10.1002\/dta.1770.","journal-title":"Drug Test Anal"},{"issue":"9","key":"1665_CR17","doi-asserted-by":"publisher","first-page":"965","DOI":"10.4155\/bio.15.253","volume":"8","author":"R Ventura","year":"2016","unstructured":"Ventura R, Matabosch X, Segura J. Bioanalytical techniques in discrimination between therapeutic and abusive use of drugs in sport. Bioanalysis. 2016;8(9):965\u201380. https:\/\/doi.org\/10.4155\/bio.15.253.","journal-title":"Bioanalysis"},{"issue":"5","key":"1665_CR18","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/dta.2343","volume":"10","author":"TT Chen","year":"2018","unstructured":"Chen TT, Tseng YC, Huang TY, Chang-Chien GP, Hsu MC. Elimination profile of triamcinolone in urine following oral administration. Drug Test Anal. 2018;10(5):860\u20134. https:\/\/doi.org\/10.1002\/dta.2343.","journal-title":"Drug Test Anal"},{"issue":"11\u201312","key":"1665_CR19","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1002\/dta.2614","volume":"11","author":"S Coll","year":"2019","unstructured":"Coll S, Matabosch X, Llorente-Onaindia J, Carb\u00f3 M, P\u00e9rez-Ma\u00f1\u00e1 C, Monfort N, et al. Elimination profile of triamcinolone hexacetonide and its metabolites in human urine and plasma after a single intra-articular administration. Drug Test Anal. 2019;11(11\u201312):1589\u2013600. https:\/\/doi.org\/10.1002\/dta.2614.","journal-title":"Drug Test Anal"},{"key":"1665_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2019.108464","volume":"151","author":"S Coll","year":"2019","unstructured":"Coll S, Monfort N, Alechaga E, Matabosch X, P\u00e9rez-Ma\u00f1\u00e1 C, Ventura R. Additional studies on triamcinolone acetonide use and misuse in sports: elimination profile after intranasal and high-dose intramuscular administrations. Steroids. 2019;151:108464. https:\/\/doi.org\/10.1016\/j.steroids.2019.108464.","journal-title":"Steroids"},{"issue":"10","key":"1665_CR21","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1111\/sms.13499","volume":"29","author":"I Athanasiadou","year":"2019","unstructured":"Athanasiadou I, Vonaparti A, Dokoumetzidis A, Saleh A, Mbeloug M, Al-Maadheed M, et al. Effect of hyperhydration on the pharmacokinetics and detection of orally administered budesonide in doping control analysis. Scand J Med Sci Sports. 2019;29(10):1489\u2013500. https:\/\/doi.org\/10.1111\/sms.13499.","journal-title":"Scand J Med Sci Sports"},{"key":"1665_CR22","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1002\/dta.2733","volume":"11","author":"M Mazzarino","year":"2019","unstructured":"Mazzarino M, Piantadosi C, De la Torre X, Botr\u00e8 F. Urinary excretion profile of prednisone and prednisolone after different administration routes. Drug Test Anal. 2019;11:1601\u201314. https:\/\/doi.org\/10.1002\/dta.2733.","journal-title":"Drug Test Anal"},{"issue":"5","key":"1665_CR23","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/dta.2678","volume":"12","author":"S Coll","year":"2020","unstructured":"Coll S, Monfort N, Matabosch X, Papakonstantinou K, P\u00e9rez-Ma\u00f1\u00e1 C, Mateus JA, et al. Budesonide use and misuse in sports: elimination profiles of budesonide and metabolites after intranasal, high-dose inhaled and oral administrations. Drug Test Anal. 2020;12(5):629\u201336. https:\/\/doi.org\/10.1002\/dta.2678.","journal-title":"Drug Test Anal"},{"issue":"2","key":"1665_CR24","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/dta.2928","volume":"13","author":"S Coll","year":"2021","unstructured":"Coll S, Monfort N, Alechaga E, Matabosch X, P\u00e9rez-Ma\u00f1\u00e1 C, Ventura R. Elimination profiles of betamethasone after different administration routes: evaluation of the reporting level and washout periods to ensure safe therapeutic administrations. Drug Test Anal. 2021;13(2):348\u201359. https:\/\/doi.org\/10.1002\/dta.2928.","journal-title":"Drug Test Anal"},{"issue":"3","key":"1665_CR25","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/dta.2966","volume":"13","author":"S Coll","year":"2021","unstructured":"Coll S, Monfort N, Alechaga E, Matabosch X, Pozo OJ, P\u00e9rez-Ma\u00f1\u00e1 C, et al. Elimination profiles of prednisone and prednisolone after different administration routes: evaluation of the reporting level and washout periods to ensure safe therapeutic administrations. Drug Test Anal. 2021;13(3):571\u201382. https:\/\/doi.org\/10.1002\/dta.2966.","journal-title":"Drug Test Anal"},{"key":"1665_CR26","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1002\/dta.3105","volume":"13","author":"K Deventer","year":"2021","unstructured":"Deventer K, Polet M, Gansbeke WV, Hooghe F, Van Hoecke H, Van Eenoo P. Investigation of the urinary excretion of prednisolone and metabolites after nasal administration: relevance to doping control. Drug Test Anal. 2021;13:1897\u2013905. https:\/\/doi.org\/10.1002\/dta.3105.","journal-title":"Drug Test Anal"},{"key":"1665_CR27","doi-asserted-by":"publisher","first-page":"107405","DOI":"10.1016\/j.ejps.2025.107405","volume":"217","author":"S Coll","year":"2026","unstructured":"Coll S, Bressan C, Monfort N, Aldea-Perona A, Carb\u00f3 M, Ventura R. Pharmacokinetic profile of dexamethasone in urine and plasma after single and multiple oral administration: relevance to doping controls. Eur J Pharm Sci. 2026;217:107405. https:\/\/doi.org\/10.1016\/j.ejps.2025.107405.","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"1665_CR28","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/dta.70032","volume":"18","author":"S Coll","year":"2026","unstructured":"Coll S, Bressan C, Monfort N, Llorente-Onaindia J, Monfort J, Santiago J, et al. Urinary and plasma profiles of betamethasone and triamcinolone acetonide following intra-articular and related administrations. Drug Test Anal. 2026;18(3):426\u201338. https:\/\/doi.org\/10.1002\/dta.70032.","journal-title":"Drug Test Anal"},{"issue":"2","key":"1665_CR29","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/cpt1979262232","volume":"26","author":"DC Garg","year":"1979","unstructured":"Garg DC, Wagner JG, Sakmar E, Weidler DJ, Albert KS. Rectal and oral absorption of methylprednisolone acetate. Clin Pharmacol Ther. 1979;26(2):232\u20139. https:\/\/doi.org\/10.1002\/cpt1979262232.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1665_CR30","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/clpt.1985.79","volume":"37","author":"H Derendorf","year":"1985","unstructured":"Derendorf H, M\u00f6lmann H, Rohdewald P, Rehder J, Schmidt EW. Kinetics of methylprednisolone and its hemisuccinate ester. Clin Pharmacol Ther. 1985;37(5):502\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"1665_CR31","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/BF00541537","volume":"30","author":"SJ Szefler","year":"1986","unstructured":"Szefler SJ, Ebling WF, Georgitis JW, Jusko J. Methlprednisolone versus prednisolone pharmacokinetics in relation to dose in adults. Eur J Clin Pharmacol. 1986;30:323\u20139. https:\/\/doi.org\/10.1007\/BF00541537.","journal-title":"Eur J Clin Pharmacol"},{"key":"1665_CR32","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/j.1365-2125.1989.tb05366.x","volume":"27","author":"SMH Al-Habet","year":"1989","unstructured":"Al-Habet SMH, Rogers HJ. Methylprednisolone pharmacokinetics after intravenous and oral administration. Br J Clin Pharmacol. 1989;27:285\u201390. https:\/\/doi.org\/10.1111\/j.1365-2125.1989.tb05366.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"1665_CR33","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/clpt.1992.80","volume":"51","author":"LE Fisher","year":"1992","unstructured":"Fisher LE, Ludwig EA, Wald JA, Sloan RR, Middleton E, Jusko WJ. Pharmacokinetics and pharmacodynamics of methylprednisolone when administered at 8 am versus 4 am. Clin Pharmacol Ther. 1992;51(6):677\u201388. https:\/\/doi.org\/10.1038\/clpt.1992.80.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1665_CR34","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/clpt.1993.167","volume":"54","author":"KM Lew","year":"1993","unstructured":"Lew KM, Ludwig EA, Milad MA, Donovan K, Middleton E, Ferry JJ, et al. Gender-based effects on merthylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1993;54(4):402\u201314.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"1665_CR35","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1023\/a:1016287104656","volume":"12","author":"H M\u00f6lmann","year":"1995","unstructured":"M\u00f6lmann H, Hochhaus G, Rohatagi S, Barth J, Derendorf H. Pharmacokinetic\/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. Pharm Rev. 1995;12(7):1096\u2013100. https:\/\/doi.org\/10.1023\/a:1016287104656.","journal-title":"Pharm Rev"},{"key":"1665_CR36","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/j.1552-4604.1997.tb04266.x","volume":"37","author":"S Rohatagi","year":"1997","unstructured":"Rohatagi S, Barth J, M\u00f6lmann H, Hochhaus G, Soldner A, M\u00f6lmann C, et al. Pharmacokinetics of methylprednisolone and prednisolone after single and multiple oral administration. J Clin Pharmacol. 1997;37:916\u201325. https:\/\/doi.org\/10.1002\/j.1552-4604.1997.tb04266.x.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1665_CR37","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1208\/s12248-024-01011-8","volume":"27","author":"R Yu","year":"2025","unstructured":"Yu R, Jusko WJ. Meta-analysis of the input and disposition of various dosage forms of methylprednisolone in healthy subjects utilizing a physiologically based pharmacokinetic model. AAPS J. 2025;27(1):24. https:\/\/doi.org\/10.1208\/s12248-024-01011-8.","journal-title":"AAPS J"},{"issue":"5","key":"1665_CR38","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/rcm.6129","volume":"26","author":"OJ Pozo","year":"2012","unstructured":"Pozo OJ, Marcos J, Matabosch X, Ventura R, Segura J. Using complementary mass spectrometric approaches for the determination of methylprednisolone metabolites in human urine. Rapid Commun Mass Spectrom. 2012;26(5):541\u201353. https:\/\/doi.org\/10.1002\/rcm.6129.","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"6","key":"1665_CR39","doi-asserted-by":"publisher","first-page":"480","DOI":"10.4103\/ijp.ijp_946_20","volume":"53","author":"AK Upadhyay","year":"2021","unstructured":"Upadhyay AK, Dubey S, Ahi S, Beotra A, Bhardwaj A, Shukla S, et al. A preliminary study on urinary excretion patterns of methylprednisolone after oral and intra-articular administration and effect on endogenous glucocorticoids profile. Indian J Pharmacol. 2021;53(6):480\u20133. https:\/\/doi.org\/10.4103\/ijp.ijp_946_20.","journal-title":"Indian J Pharmacol."},{"key":"1665_CR40","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/s0026-0495(98)90064-6","volume":"147","author":"PH Barrett","year":"1998","unstructured":"Barrett PH, Bell BM, Cobelli C, Golde H, Schumitzky A, Vicini P, et al. SAAM II: simulation, analysis and modelling software for tracer and pharmacokinetics studies. Metabolism. 1998;147:484\u201392. https:\/\/doi.org\/10.1016\/s0026-0495(98)90064-6.","journal-title":"Metabolism"},{"key":"1665_CR41","doi-asserted-by":"publisher","DOI":"10.1201\/b14095","volume-title":"Pharmacokinetics","author":"M Gibaldi","year":"1982","unstructured":"Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker; 1982.","edition":"2"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01665-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01665-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01665-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:17:08Z","timestamp":1786461428000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01665-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1665"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01665-x","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Sergi Coll, Claudia Bressan, N\u00faria Monfort, Ana Aldea-Perona, Marcel\u00b7l\u00ed Carb\u00f3 and Rosa Ventura have no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflicts of interest\/competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval of the study was granted by the local research ethical committee (Comit\u00e8 \u00c8tic d\u2019Investigaci\u00f3 Cl\u00ednica CEIC-Parc de Salut Mar, Barcelona, Spain) and the Spanish Medicines Agency (EudraCT protocol number 2020-004596-41).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets generated and\/or analyzed during the current study are not publicly available because of confidentiality agreements and privacy restrictions. Data may be available from the corresponding author upon reasonable request, subject to institutional approval and compliance with applicable confidentiality and data protection regulations.","order":5,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SC: conceptualization, methodology, analysis, data curation, writing, reviewing. CB: methodology, analysis, data curation, reviewing. NM: resources, methodology, supervision, reviewing. AA-P: clinical study, reviewing. MC: data curation, pharmacokinetic analysis, writing, reviewing. RV: conceptualization, funding acquisition, supervision, writing, reviewing.","order":7,"name":"Ethics","label":"Authors\u2019 contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}